Orthox is a privately held UK company developing tissue regenerative implants which enable patients who have suffered injuries to the cartilage and meniscus in the knee to return to a fully active, pain-free lifestyle. This is achieved through Orthox’s proprietary technology, FibroFix™: a natural biomaterial which is uniquely suited to addressing injuries to cartilage tissue.
FibroFix™ is delivered in smooth, anatomically shaped devices which combine exceptional strength and resilience with the capacity to support regeneration of the patients own tissue. This allows FibroFix™ implants to assume the function of the injured tissue while being supplemented by long term regenerative repair.
Injuries to the cartilage in the knee cause crippling disability in both young and old patients, often leading to osteoarthritis and eventual need for replacement of the joint. The developed world is facing an epidemic of total knee replacement procedures despite concerns about the lifespan of joint replacement devices, particularly when implanted in younger patients, and the procedure being targeted for cuts due to the expense of joint replacement. Nonetheless, experts predict a more than 500% rise in this operation over the next two decades* as increasingly younger patients demand this major surgery to resolve immobility and chronic knee pain.
To prevent total knee replacement, many patients who suffer injury to their knee cartilage are advised to limit activity or risk deterioration of the joint. At Orthox we offer an alternative: strong, resilient, natural implants capable of restoring knee function while allowing the body’s own cells to grow through and integrate with the device. We believe FibroFix™ products will give patients both the rapid functional recovery to quickly resume a normal lifestyle, and the regenerative repair needed to safeguard the long term health of the joint.